When Should One Perform Pharmacoepidemiologic Studies?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The decision to conduct a pharmacoepidemiologic study can be viewed as similar to the regulatory decision about whether to approve a drug for marketing or the clinical decision about whether to prescribe a drug. In each case, decision making involves weighing the costs and risks of a therapy against its benefits. Because a central consideration is one's willingness to tolerate risk-whether from the perspectives of a manufacturer, regulator, academician, or clinician-this chapter provides also a discussion of the difference between safety and risk. It concludes with a discussion of the determinants of one's tolerance of risk.

Original languageEnglish (US)
Title of host publicationPharmacoepidemiology, Fifth Edition
PublisherWiley-Blackwell
Pages62-70
Number of pages9
ISBN (Print)0470654759, 9780470654750
DOIs
StatePublished - Jan 3 2012

Fingerprint

Marketing
Pharmaceutical Preparations
Decision Making
Safety
Costs and Cost Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Keywords

  • Adverse drug reaction
  • Decision making
  • Drug regulation
  • Drug safety
  • Pharmacoepidemiologic study
  • Postmarketing study
  • Risk tolerance
  • Risk-benefit

Cite this

Strom, B. (2012). When Should One Perform Pharmacoepidemiologic Studies? In Pharmacoepidemiology, Fifth Edition (pp. 62-70). Wiley-Blackwell. https://doi.org/10.1002/9781119959946.ch5
Strom, Brian. / When Should One Perform Pharmacoepidemiologic Studies?. Pharmacoepidemiology, Fifth Edition. Wiley-Blackwell, 2012. pp. 62-70
@inbook{792af4ab33104c86960b16f06bd444a9,
title = "When Should One Perform Pharmacoepidemiologic Studies?",
abstract = "The decision to conduct a pharmacoepidemiologic study can be viewed as similar to the regulatory decision about whether to approve a drug for marketing or the clinical decision about whether to prescribe a drug. In each case, decision making involves weighing the costs and risks of a therapy against its benefits. Because a central consideration is one's willingness to tolerate risk-whether from the perspectives of a manufacturer, regulator, academician, or clinician-this chapter provides also a discussion of the difference between safety and risk. It concludes with a discussion of the determinants of one's tolerance of risk.",
keywords = "Adverse drug reaction, Decision making, Drug regulation, Drug safety, Pharmacoepidemiologic study, Postmarketing study, Risk tolerance, Risk-benefit",
author = "Brian Strom",
year = "2012",
month = "1",
day = "3",
doi = "10.1002/9781119959946.ch5",
language = "English (US)",
isbn = "0470654759",
pages = "62--70",
booktitle = "Pharmacoepidemiology, Fifth Edition",
publisher = "Wiley-Blackwell",
address = "United Kingdom",

}

Strom, B 2012, When Should One Perform Pharmacoepidemiologic Studies? in Pharmacoepidemiology, Fifth Edition. Wiley-Blackwell, pp. 62-70. https://doi.org/10.1002/9781119959946.ch5

When Should One Perform Pharmacoepidemiologic Studies? / Strom, Brian.

Pharmacoepidemiology, Fifth Edition. Wiley-Blackwell, 2012. p. 62-70.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - When Should One Perform Pharmacoepidemiologic Studies?

AU - Strom, Brian

PY - 2012/1/3

Y1 - 2012/1/3

N2 - The decision to conduct a pharmacoepidemiologic study can be viewed as similar to the regulatory decision about whether to approve a drug for marketing or the clinical decision about whether to prescribe a drug. In each case, decision making involves weighing the costs and risks of a therapy against its benefits. Because a central consideration is one's willingness to tolerate risk-whether from the perspectives of a manufacturer, regulator, academician, or clinician-this chapter provides also a discussion of the difference between safety and risk. It concludes with a discussion of the determinants of one's tolerance of risk.

AB - The decision to conduct a pharmacoepidemiologic study can be viewed as similar to the regulatory decision about whether to approve a drug for marketing or the clinical decision about whether to prescribe a drug. In each case, decision making involves weighing the costs and risks of a therapy against its benefits. Because a central consideration is one's willingness to tolerate risk-whether from the perspectives of a manufacturer, regulator, academician, or clinician-this chapter provides also a discussion of the difference between safety and risk. It concludes with a discussion of the determinants of one's tolerance of risk.

KW - Adverse drug reaction

KW - Decision making

KW - Drug regulation

KW - Drug safety

KW - Pharmacoepidemiologic study

KW - Postmarketing study

KW - Risk tolerance

KW - Risk-benefit

UR - http://www.scopus.com/inward/record.url?scp=84888685055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888685055&partnerID=8YFLogxK

U2 - 10.1002/9781119959946.ch5

DO - 10.1002/9781119959946.ch5

M3 - Chapter

SN - 0470654759

SN - 9780470654750

SP - 62

EP - 70

BT - Pharmacoepidemiology, Fifth Edition

PB - Wiley-Blackwell

ER -

Strom B. When Should One Perform Pharmacoepidemiologic Studies? In Pharmacoepidemiology, Fifth Edition. Wiley-Blackwell. 2012. p. 62-70 https://doi.org/10.1002/9781119959946.ch5